XNYS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: ResMed posted Q3 fiscal 2026 revenue of $1.43B, up 10.8% from $1.29B in the year-ago quarter, with GAAP gross margin expanding 290 basis points to 62.2%.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 5/7/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | -4,991 | — | — |
| 5/7/2026 | Farrell Michael J. | Chairman and CEO | SELL | -4,991 | $208 | $1,037,233 |
| 5/7/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | 4,991 | $146 | $730,383 |
| 4/7/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | 4,991 | $146 | $730,383 |
| 4/7/2026 | Farrell Michael J. | Chairman and CEO | SELL | -4,991 | $226 | $1,125,486 |
| 4/7/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | -4,991 | — | — |
| 4/1/2026 | Sandercock Brett | Chief Financial Officer | SELL | -1,000 | $224 | $224,310 |
| 4/1/2026 | FARRELL PETER C | — | SELL | -2,000 | $225 | $450,000 |
| 3/9/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | 4,991 | $146 | $730,383 |
| 3/9/2026 | Farrell Michael J. | Chairman and CEO | SELL | -4,991 | $251 | $1,252,902 |
| 3/9/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | -4,991 | — | — |
| 3/4/2026 | FARRELL PETER C | — | SELL | -2,000 | $260 | $520,440 |
| 3/2/2026 | Sandercock Brett | Chief Financial Officer | SELL | -1,000 | $254 | $254,300 |
| 2/9/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | 4,991 | $146 | $730,383 |
| 2/9/2026 | Farrell Michael J. | Chairman and CEO | SELL | -4,991 | $274 | $1,366,436 |
| 2/9/2026 | Farrell Michael J. | Chairman and CEO | OPTION_EXERCISE | -4,991 | — | — |
| 2/4/2026 | FARRELL PETER C | — | SELL | -2,000 | $251 | $502,620 |
| 2/4/2026 | Rider Michael J | Global General Counsel | SELL | -50 | $260 | $13,000 |
| 2/2/2026 | Sandercock Brett | Chief Financial Officer | SELL | -1,000 | $257 | $257,030 |
| 1/7/2026 | FARRELL PETER C | — | SELL | -2,000 | $249 | $497,660 |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 5/7/2026 | Farrell Michael J. | — | 4,991 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| 5/4/2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 18,882,403 | $4,548,204,411 | — | 1/29/2026 |
| BlackRock | 11,691,961 | $2,238,075,134 | — | 8/13/2024 |
| State Street | 6,625,408 | $1,595,862,025 | — | 2/13/2026 |
| JP Morgan Chase | 605,408 | $145,824,771 | — | 2/11/2026 |
| Fidelity (FMR) | 415,813 | $100,156,849 | — | 2/17/2026 |
| AQR Capital | 255,884 | $61,634,645 | — | 2/17/2026 |
| Millennium Management | 165,442 | $39,850,015 | — | 2/17/2026 |
| Citadel Advisors | 161,300 | $38,852,331 | — | 2/17/2026 |
| Bridgewater Associates | 32,924 | $7,930,404 | — | 2/13/2026 |
| DE Shaw | 23,589 | $5,681,882 | — | 2/17/2026 |
| Point72 | 1,200 | $289,044 | — | 2/17/2026 |